Polynovo Limited · ASX:PNV
Polynovo — FY2026 Earnings Presentation
19 slides from Polynovo's earnings presentation, Aug 26, 2026
Slide 1: FY26 Results
FY26 Results (in conjunction with Appendix 4€) Proven platform. Scaling for growth. Bruce Peatey Jan Gielen ceo CFO $3) PolyNovo: 26 August 2026
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PolyNovo Limited (ASX: PNV) (“PolyNovo”) for general information purposes only and is current as at the date of this presentation. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of
Slide 3: Leadership in Burns with a Future in Complex Wounds
Leadership in Burns with a Future in Complex Wounds Large TBSA burns Traumatic wounds Complex wounds Image supplied by Townsville University Hospital. 3 POLYNOVO FY26 RESULTS
Slide 4: Strengthening the Foundation for Future Growth
Strengthening the Foundation for Future Growth COMMERCIAL MOMENTUM GROWING OPPORTUNITY Finalised the Clinical Study Report for PolyNovo’s U.S. pivotal randomised 89.6% commercial sales growth controlled trial funded by BARDA1 Regulatory clearance for 252 new hospital accounts NovoSorb® BTM in eight
Slide 5: FY26 Financial Highlights
FY26 Financial Highlights NovoSorb® Group Sales NovoSorb® U.S. Sales NovoSorb® ROW Sales +16.7% +21.3% in constant currency +15.6% +21.1% in constant currency +20.0% +21.9% in constant currency FY26 FY25 FY26 FY25 FY26 FY25 AUD $138.4m $118.6m AUD $102.1m $88.4m AUD $36.3m $30.3m EBITDA1 Cash and Ca
Slide 6: Complex Wounds Are Driving the Next Phase of Growth
Complex Wounds Are Driving the Next Phase of Growth Growth outside burns demonstrates the expanding clinical utility of the NovoSorb platform 3-year U.S. Sales CAGR Large burns Other indications Large burns: 19.1% Other indications: 52.8% All indications: 30.9% H1 2023 H2 2023 H1 2024 H2 2024 H1 202
Slide 7: NovoSorb MTX: Accelerating Adoption
NovoSorb® MTX: Accelerating Adoption “NovoSorb® technology is the second disruptive technology in my 22 years of surgical practice Commercial footprint that has profoundly impacted complex lower extremity soft tissue reconstruction in the complicated patient. The ease of use, versatility, bacterial
Slide 8: Evidence Supporting Broader Adoption
Evidence Supporting Broader Adoption Mixed Articles and abstracts Academic text chapters Aetiology 19% Other 535 9 Indications 402 Burn 45% 36% 1 Pre-FY26 FY26 Pre-FY26 FY26 Burn publications include studies are exclusively burn-related indications. Other indications include studies exclusively focu
Slide 9: Multiple Growth Levers Across a Global Footprint
Multiple Growth Levers Across a Global Footprint Americas APAC Sales up 20.2% cc, Sales up 37.8% cc, YOY YOY Submit and Sustain growth capitalise on the PMA momentum in non-burns applications Launch NovoSorb® SynPath® and extend Accelerate outpatient presence NovoSorb® MTX adoption in Australia, Hon
Slide 10: Proven Platform. Scaling for Growth.
Proven Platform. Scaling for Growth. Our strategy: translating clinical leadership into long-term value Scale the Core Leverage the Platform Build a Global Enterprise Advance leadership in burn Shape the next generation Augment manufacturing care in key markets of NovoSorb innovation footprint Expan
Slide 11: FY27: Converting Opportunity into Growth
FY27: Converting Opportunity into Growth Launch Increase Deliver greater Secure PMA NovoSorb® innovation operating approval and SynPath® for Accelerate velocity and leverage and evidence-based the U.S. NovoSorb® MTX build business profitability as expansion outpatient adoption development the busine
Slide 12: Financial Results
‘33 PolyNovo" Healing. Redefined. Financial Results
Slide 13: FY26: Strong Commercial Performance
FY26: Strong Commercial Performance Global commercial sales $138.4m Highlights: $118.7m $12.6m • Group sales A$138.4m +16.7% on LY / +21.3% CC $6.7m • U.S. sales A$102.1m +15.6% on LY / +21.1% CC • ROW sales A$36.3m +20.0% on LY / +21.9% CC $125.8m $112.0m • NovoSorb® BTM sales • NovoSorb® MTX sales
Slide 14: FY26: United States Highlights
FY26: United States Highlights Highlights: U.S. commercial product sales NovoSorb MTX 120.0 commercial product sales Strong sales growth +21.1% cc 14.0 +92.7% cc 0.0% • Total U.S. sales growth 15.6% / 21.1% cc 100.0 • NovoSorb MTX sales growth: 83.7% / $102.1m 12.0 92.7% cc $12.2m • Profitable, incr
Slide 15: FY26: ROW Highlights
FY26: ROW Highlights $40.0m 100.0% Rest of World commercial sales 20.0% 0.0% $35.0m 29.1% $36.3m -100.0% Highlights: $30.0m -200.0% • Sales A$36.3m up 20.0% on LY / 21.9% CC $30.3m $25.0m -300.0% • High growth markets (constant currency): $23.3m -400.0% • Turkey 79.0% $20.0m -500.0% • Hong Kong 49.9
Slide 16: FY26: Income Statement Summary
FY26: Income Statement Summary Income Statement ($m) FY26 FY25 Change % Revenue: REVENUE NovoSorb Product Sales 138.4 118.6 16.7% • NovoSorb sales up 21.3% in constant currency (16.7% reported) BARDA 5.3 8.6 -38.8% • BARDA revenue declined as expected with the pivotal burns trial concluding Other In
Slide 17: FY26: Capital Efficient Growth
FY26: Capital Efficient Growth Highlights: Cash flow breakdown • A$35.4m cash on hand and cash equivalents $23.1m • A$23.1m cash flow from operations • A$9.4m free cash flow1 • A$13.8m capital expenditure comprising: ($13.8m) • A$12.4m for completion of new manufacturing ($5.3m) facility ($2.1m) • A
Slide 18: Subscribe for updates
PolyNovo: Healing. Redefined. Subscribe for updates
Slide 19: FY26 Balance Sheet Summary
FY26 Balance Sheet Summary Balance Sheet ($m) FY26 FY25 Change % Cash and cash equivalent 35.4 33.5 5.7% Trade and other receivables 22.2 24.4 -9.0% Inventories 9.8 14.5 -32.4% Other 6.5 4.7 38.3% • Other line item includes insurance receivable of $1.6m Total current assets 73.9 77.1 -4.2% Total ass